// App-Quantinova.ai

TH-OR18 : SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis

Researchers

Presenter

  • Chertow GlennMatthew

Principal Investigators

  • Raggi Paolo

  • Bellasi Antonio

  • Bushinsky DavidA

  • Bover Jordi

  • Rodriguez Mariano

  • Ketteler Markus

  • Sinha Smeeta

  • Garg Rekha

  • Padgett ClaireS

  • Perell Joan

  • Gold Alex

Medical Centers

  • Department of Medicine, Stanford University Medical Center, Palo Alto, California, United States

  • Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada

  • Research Innovation and Brand Reputation Unit ASST Papa Giovanni XXIII Bergamo Italy

  • Department of Biomedical Engineering, University of Rochester Medical Center, Rochester, New York, United States

  • Department of Nephrology Fundació Puigvert and Universitat Autònoma IIB Sant Pau REDinREN Barcelona Spain

  • Nephrology Unit Hospital Universitario Reina Sofia IMIBIC REDinREN Cordoba Spain

  • Department of General Internal Medicine and Nephrology Robert-Bosch-Krankenhaus Stuttgart Germany

  • Department of Dietetics, Salford Royal Foundation Trust, Salford, United Kingdom

  • Research and Development Sanifit (now with PharmaDRS Consulting) San Diego California United States

  • Research and Development Sanifit San Diego California United States

  • Research and Development Sanifit Palma Spain

Locations

  • United States

  • Canada

  • Italy

  • Spain

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Complex calcified coronary artery lesions

  • Diabetes

  • Coronary Artery Disease

Biomarkers

  • Carbonic anhydrase II

Drug/Treatment

  • Ergocalciferol

  • Warfarin

  • Hexasodium phytate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved